Galantamine hydrobromide is a Small Molecule owned by Johnson & Johnson, and is involved in 51 clinical trials, which were completed.

Galantamine is a reversible competitive acetylcholinesterase inhibitor. It prevents the hydrolysis of acetycholine, leading to an increased concentration of acetylcholine at cholinergic synapses. An increased activity in the cholinergic system improves cognitive function in patients with dementia of the Alzheimer type.

The revenue for Galantamine hydrobromide is expected to reach a total of $33m through 2026. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Galantamine hydrobromide NPV Report.

Galantamine hydrobromide is currently owned by Johnson & Johnson. Takeda Pharmaceutical is the other company associated in development or marketing of Galantamine hydrobromide.

Galantamine hydrobromide Overview

Galantamine hydrobromide (Reminyl / Razadyne) is a phenanthrene alkaloid acts as nootropic agent. It is formulated as film coated tablets and solution for oral route of administration. It is indicated for the treatment of mild to moderate dementia of the alzheimer's type.

Takeda Pharmaceutical Overview

Takeda Pharmaceutical (Takeda) is a research-based pharmaceutical company which focuses on the discovery, development, manufacturing, marketing, commercialization, import and export of pharmaceutical drugs. The company offers products in the areas of rare diseases, gastrointestinal, oncology, neuroscience, vaccines, and plasma-derived therapies. Takeda has facilities in Japan, Argentina, Brazil, Mexico, the US, Denmark, Norway, Europe, Poland, Russia, Spain, Switzerland, China and India, Canada among others. It markets products directly and through a network of wholesale distributors, retail chains and other purchasing groups worldwide. Takeda has partnership with academic institutions, small biotech, and large pharmaceutical companies. It has presence in the Americas, Europe, and Asia, among others. Takeda is headquartered in Tokyo, Japan.

The company reported revenues of (Yen) JPY3,569,006 million for the fiscal year ended March 2022 (FY2022), an increase of 11.6% over FY2021. In FY2022, the company’s operating margin was 12.5%, compared to an operating margin of 18.8% in FY2021. In FY2022, the company recorded a net margin of 6.4%, compared to a net margin of 11.8% in FY2021. The company reported revenues of JPY1,002,307 million for the second quarter ended September 2022, an increase of 3.1% over the previous quarter.

Quick View – Galantamine hydrobromide

Report Segments
  • Innovator (NME)
Drug Name
  • Galantamine hydrobromide
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.